EICHOR
● Unknown
Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction
Condition: Cardiovascular Risk Factor · Cardiovascular Diseases · Cardiovascular Stroke · Sponsor: LIB Therapeutics LLC
About this study
This study is to assess LDL-C reductions at Week 52 with monthly (Q4W \[≤31 days\]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with CVD, or at high risk for CVD, on a stable diet and oral LDL-C lowering drug therapy
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (6)
| Sterling Research Group | Cincinnati, Ohio, United States | — |
| The Lindner Research Center | Cincinnati, Ohio, United States | — |
| Metabolic & Atherosclerosis Research Center (MARC) | Cincinnati, Ohio, United States | — |
| G.B. Pant Institute of Postgraduate Medical Education & Research | New Delhi, India | — |
| Department of Medicine, Hadassah University Hospital | Jerusalem, Israel | — |
| Rabin Medical Center, Beilinson Hospital, | Petah Tikva, Israel | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04806893